NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC).

MicroRNA study provides biomarker for survival in small cell lung cancer.

SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.

SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced a clinical and regulatory update on its lead product candidate, picoplatin.

Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC).